Hepatitis B Virus

Potential new treatment described

Published in Hepatitis Weekly, November 11th, 2002

Researchers from the Scripps Research Institute in La Jolla, California report that the compound interleukin-18 (IL-18) may control replication of the hepatitis B virus (HBV) and be an effective therapy for patients already being treated for chronic hepatitis.

Their results appear in the November 2002 issue of the Journal of Virology.

In the study, HBV-infected mice were treated with IL-18 and then monitored for varying levels of HBV DNA in the liver. HBV DNA levels significantly decreased after 4 hours and were almost undetectable after 24 hours.

"In conclusion, our observation that IL-18 can inhibit HBV replication in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry